KYNTRA BIO, INC. 8-K

What Happened

• Kyntra Bio, Inc. announced financial results for the quarter and year ended December 31, 2025 in a press release dated March 16, 2026. The company filed Form 8-K (Item 2.02) on March 16, 2026 to furnish that press release, which is included as Exhibit 99.1 to the filing. The 8-K was signed by David DeLucia, Senior Vice President and Chief Financial Officer.

Key Details

• Filing date: March 16, 2026 (Form 8-K, Item 2.02 and Item 9.01).
• Reporting periods covered: quarter and fiscal year ended December 31, 2025.
• Press release: furnished as Exhibit 99.1 and incorporated by reference into the 8-K.
• Signature: David DeLucia, SVP & CFO, authorized the filing.

Why It Matters

• This 8-K notifies investors that Kyntra Bio has publicly released its latest quarterly and full-year financial results; the detailed figures and metrics are in the furnished press release (Exhibit 99.1). Investors should review that press release for revenue, earnings, guidance and other financial metrics that could affect the stock. The 8-K itself does not reproduce the full financial statements but serves to formally disclose the results to the market.